Item Details
AbbVie agrees cancer research partnership worth up to $2.54 billion
Announced on 19 November, pharmaceutical group AbbVie has agreed a research and development partnership with German biotechnology company Disco Pharmaceuticals. The agreement includes $40 million upfront and up to $2.5 billion in milestone payments, alongside royalties, to develop advanced cancer treatments. HPC could identify biotechnology companies, pharmaceutical partners and investors interested in similar licensing and research opportunities.
Get in Touch
We’ll get back to you shortly.